Systemic treatment of malignant pleural mesothelioma

Future Oncology

Volumn 8, Issue 3, 2012, Pages 293-305

  Grosso, Federica ^a   Scagliotti, Giorgio Vittorio ^b  

^a SS Antonio e Biagio General Hospital   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

chemotherapy; drug therapy; lung cancer; malignant pleural mesothelioma; mesothelioma; pleural neoplasm; systemic treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MITOMYCIN; NAVELBINE; OXALIPLATIN; PEMETREXED; RALTITREXED; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; EARLY INTERVENTION; HUMAN; MAINTENANCE CHEMOTHERAPY; MALIGNANT PLEURA MESOTHELIOMA; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PLEURA; PLEURAL NEOPLASMS; QUINAZOLINES; THIOPHENES; TREATMENT OUTCOME;

EID: 84858410873     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.14     Document Type: Review

References (100)

1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005. Crit. Rev. Toxicol. 39, 576-588 (2009)
2. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the north Western Cape province. Br. J. Ind. Med. 17, 260-271 (1960)
3. Nakano T. Current therapies for malignant pleural mesothelioma. Environ. Health Prev. Med. 13, 75-83 (2008)
4. Larson T, Melnikova N, Davis SI et al. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999-2002. Int. J. Occup. Environ. Health 13, 398-403 (2007
5. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. The mesothelioma epidemic in Western Europe: An update. Br. J. Cancer 90(5), 1022-1024 (2004
6. Price B, Ware A. Mesothelioma trends in the United States: An update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am. J. Epidemiol. 159, 107-112 (2004
7. Pass HI, Vegelzang N, Hahn S et al. Malignant pleural mesothelioma. Curr. Probl. Cancer 28, 93-174 (2004
8. Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD. Survival afterconservative (palliative) management of pleural malignant mesothelioma. J. Surg. Oncol. 78(3), 171-174 (2001
9. Milano MT, Zhang H. Malignant pleural mesothelioma: A population-based study of survival. J. Thorac. Oncol. 5(11), 1841-1848 (2010
10. Steele JP. Prognostic factors for mesothelioma. Hematol. Oncol. Clin. North Am. 19(6), 1041-1052 (2005
11. Krug LM, Pass HI, Rusch VW et al. Multicenter Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27(18), 3007-3013 (2009
12. Van Schil PE, Baas P, Gaafar R et al. Trimodality therapy for malignant pleural mesothelioma: Results from an EORTC Phase II multicentre trial. Eur. Respir. J. 36(6), 1362-1369 (2010
13. De Perrot M, Feld R, Cho BC et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 20, 27(9), 1413-1418 (2009
14. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 18(7), 1196-1202 (2007
15. Cao C, Yan TD, Bannon PG, McCaughan BC. Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann. Surg. Oncol. 18(10), 2973-2979 (2011
16. Treasure T, Lang-Lazdunski L, Waller D et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 12(8), 763-772 (2011
17. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J. Thorac. Cardiovasc. Surg. 135(3), 620-626 (2008
18. Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 33(1), 83-88 (2008
19. Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 371(9625), 1685-1694 (2008
20. O'Brien ME, Watkins D, Ryan C et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: The MED trial. Ann. Oncol. 17(2), 270-275 (2006
21. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer 38(2), 111-121 (2002
22. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 15(14), 36-44 (2003
23. Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): Psychometric properties of the LCSS-Meso. Support Care Cancer 14(1), 11-21 (2006
24. Vogelzang NJ, Emri S, Boyer MJ et al. Effect of folic acid and vitamin B12 supplementation on risk benefit ratio from Phase III study of pemetrexed and cisplatin versus cisplatin in malignant pleural mesothelioma. J. Clin. Oncol. 22, Abstract 2644 (2003
25. Ceresoli GL, Zucali PA, Favaretto AG et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. 24(9), 1443-1448 (2006
26. Castagneto B, Botta M, Aitini E et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann. Oncol. 19(2), 370-373 (2008
27. Ceresoli GL, Castagneto B, Zucali PA et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: Combined analysis of two Phase II trials. Br. J. Cancer 99(1), 51-56 (2008
28. Santoro A, O'Brien ME, Stahel RA et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J. Thorac. Oncol. 3(7), 756-763 (2008
29. Van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23(28), 6881-6889 (2005
30. Bottomley A, Gaafar R, Manegold C et al. Short-term treatment-related symptoms and quality of life: Results from an international randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J. Clin. Oncol. 24(9), 1435-1442 (2006
31. Van Den Bogaert DP, Pouw EM, Van Wijhe G et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 1(1), 25-30 (2006
32. Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin. Oncol. 29(1), 70-76 (2002
33. Kalmadi SR, Rankin C, Kraut MJ et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A Phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60(2), 259-263 (2008
34. Favaretto AG, Aversa SM, Paccagnella A et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric Phase II study. Cancer 97(11), 2791-2797 (2003
35. Schutte W, Blankenburg T, Lauerwald K et al. A multicenter Phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin. Lung Cancer 4(5), 294-297 (2003
36. Berghmans T, Lafitte JJ, Paesmans M et al. A Phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 50(1), 75-82 (2005
37. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11(3), 118-120 (1998
38. Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21(8), 1556-1561 (2003
39. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 18(23), 3912-3917 (2000
40. Steele JP, O'Doherty CA, Shamash J et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann. Oncol. 12(4), 497-499 (2001
41. Manegold C, Symanowski J, Gatzemeier U et al. Second-line (post-study) chemotherapy received by patients treated in the Phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. 16(6), 923-927 (2005
42. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 26(10), 1698-1704 (2008
43. Jänne PA, Wozniak AJ, Belani CP et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a Phase IIIb expanded access program. J. Thorac. Oncol. 1(6), 506-512 (2006
44. Taylor P, Castagneto B, Dark G et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: Results of an International Expanded Access Program. J. Thorac. Oncol. 3(7), 764-771 (2008
45. Stebbing J, Powles T, McPherson K et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63(1), 94-97 (2009
46. Zucali PA, Ceresoli GL, Garassino I et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112(7), 1555-1561 (2008
47. Okuno SH, Delaune R, Sloan JA et al. A Phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: A North Central Cancer Treatment Study, N0021. Cancer 112(8), 1772-1779 (2008
48. Ceresoli GL, Zucali PA, De Vincenzo F et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 72(1), 73-77 (2011
49. Zucali PA, Simonelli M, Michetti G et al. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. Lung Cancer 75(3), 360-367 (2012
50. Razak AR, Chatten KJ, Hughes AN. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): A second line treatment option. Lung Cancer 60(2), 294-297 (2008
51. Hayashi H, Okamoto I, Ichikawa Y et al. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. Int. J. Clin. Oncol. 15(5), 497-499 (2010
52. Righi L, Papotti MG, Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J. Clin. Oncol. 28(9), 1534-1539 (2010
53. Nutt JE, Razak AR, O'Toole K et al. The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br. J. Cancer 102(3), 553-560 (2010
54. Wei SZ, Zhan P, Shi MQ et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: A systematic review and meta-analysis. Med. Oncol. 28(1), 315-321 (2011
55. Kotsakis A, Georgoulias V. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opin. Pharmacother. 11(14), 2363-2389 (2010
56. O'Byrne KJ, Edwards JG, Waller DA. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 45(Suppl. 1), S45-S48 (2004
57. Mossman BT, Gruenert DC. SV40, growth factors, and mesothelioma: Another piece of the puzzle. Am. J. Respir. Cell Mol. Biol. 26(2), 167-170 (2002
58. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ. EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54(3), 399-407 (2006
59. Destro A, Ceresoli GL, Falleni M et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51(2), 207-215 (2006
60. Govindan R, Kratzke RA, Herndon JE 2nd et al. Gefitinib in patients with malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 11(6), 2300-2304 (2005
61. Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J. Clin. Oncol. 25(17), 2406-2413 (2007
62. Jackman DM, Kindler HL, Yeap BY et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113(4), 808-814 (2008
63. Velcheti V, Kasai Y, Viswanathan AK, Ritter J, Govindan R. Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J. Thorac. Oncol. 4(4), 559 (2009
64. Ohta Y, Shridhar V, Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 81(1), 54-61 (1999
65. Yasumitsu A, Tabata C, Tabata R et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J. Thorac. Oncol. 5(4), 479-483 (2010
66. Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193(4), 468-475 (2001
67. Karrison T, Kindler HL, Gandara DR et al. Final analysis of a multicenter, double blind, placebo controlled Phase II trial of gemcitabine/cisplatin (CG) plus bevacizumab (B) or placebo (P) in patients with malignantmesothelioma. J. Clin. Oncol. 25(Suppl. 18), Abstract 7526 (2007
68. Zalcman G, Margery J, Scherpereel A et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized Phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J. Clin. Oncol. 28(Suppl. 15), Abstract 7020 (2010
69. Jahan TM, Gu L, Wang X et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A Phase II study by the Cancer and Leukemia Group B (CALGB 30107). J. Clin. Oncol. 24 (18S), Abstract 7081 (2006
70. Garland LL, Chansky K, Wozniak AJ et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J. Thorac. Oncol. 6(11), 1938-1945 (2011
71. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48(2), 291-296 (2005
72. Pavlakis N, Abraham R, Harvie R et al. Thalidomide alone or in combination with cisplatine/gemcitabine in malignant pleural mesothelioma (MM); interim results from two parallel non randomized Phase II studies. Lung Cancer 41(Suppl. 2), S11 (2003
73. Baas P, Buikhuisen W, Dalesio O et al. A multicenter, randomized Phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J. Clin. Oncol. 29(15), Abstract 7006 (2011
74. Dubey S, Jänne PA, Krug L et al. A Phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307. J. Thorac. Oncol. 5(10), 1655-1661 (2010
75. Mutri V, Pinto C, Giaquinta S et al. Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients: Italian SoMe Study. J. Clin. Oncol. 29, Abstract 7087 (2011
76. Nowak AK, Millward M, Francis R. J et al. Final results of a Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J. Clin. Oncol. 28(15), Abstract 7036 (2010
77. Filiberti R, Marroni P, Neri M et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol. 26(5), 221-226 (2005
78. Edwards JG, Cox G, Andi A et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br. J. Cancer 85(6), 863-868 (2001
79. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: A Phase II trial. Lung Cancer 50(1), 83-86 (2005
80. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 59(1), 149-150 (2007
81. Bertino P, Porta C, Barbone D et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed. Thorax 62(8), 690-695 (2007
82. Tsao AS, He D, Saigal B et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol. Cancer Ther. 6(7), 1962-1972 (2007
83. Tsao AS, Wistuba II, Mehran RJ et al. Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. J. Clin. Oncol. 28(15), Abstract 7042 (2010
84. Dudek A, Pang H, Kratzke A et al. A Phase II study of dasatinib (D) in patients (pts) with previously treated mesothelioma. J. Clin. Oncol. 28(15), Abstract 7037 (2010
85. Altomare DA, You H, Xiao GH et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40), 6080-6089 (2005
86. López-Lago MA, Okada T, Murillo MM, Socci N, Giacotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 29(15), 4235-4249 (2009
87. Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J. Thorac. Cardiovasc. Surg. 139(5), 1233-1240 (2010
88. Wagner AJ, Bendell JC, Dolly S et al. A first-in-human Phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol. 29(Suppl.), Abstract 3020 (2011
89. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell Mol. Biol. 25(5), 562-568 (2001
90. Krug LM, Curley T, Schwartz L et al. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer 7(4), 257-261 (2006
91. Krug LM, Kindler H, Calvert H et al. VANTAGE 014: Vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: A Phase III, randomized, double-blind, placebo-controlled trial Eur. J. Cancer 47, 2-3 (2011
92. Scherpereel A, Berghmans T, Lafitte JJ et al. Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A Phase II study. Eur. Respir. J. 37(1), 129-135 (2011
93. Gregorc V, Zucali PA, Santoro A et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol. 28(15), 2604-2611 (2010
94. Shapiro GI, Tibes R, Gordon MS et al. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin. Cancer Res. 17(10), 3431-3442 (2011
95. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. J. Cancer 44(1), 46-53 (2008
96. Hassan R, Schweizer C, Lu KF et al. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 68(3), 455-459 (2010
97. Thomas AM, Santarsiero LM, Lutz ER et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200(3), 297-306 (2004
98. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin. Cancer Res. 13(23), 7166-7171 (2007
99. Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43(10), 1022-1025 (2011)
100. Balatti V, Maniero S, Ferracin M et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J. Thorac. Oncol. 6(5), 844-851 (2011)